164 related articles for article (PubMed ID: 22105318)
1. Chemotherapy for bladder cancer in patients with impaired renal function.
Nicholson S
Nat Rev Urol; 2011 Nov; 9(1):52-7. PubMed ID: 22105318
[TBL] [Abstract][Full Text] [Related]
2. Management of advanced bladder cancer in patients with impaired renal function.
Bournakis E; Dimopoulos MA; Bamias A
Expert Rev Anticancer Ther; 2011 Jun; 11(6):931-9. PubMed ID: 21707290
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy for bladder cancer.
Sonpavde G; Lerner SP
Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
[TBL] [Abstract][Full Text] [Related]
4. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
Hoshino K; Kikuchi E; Tanaka N; Akita H; Ito Y; Miyajima A; Jinzaki M; Oya M
Jpn J Clin Oncol; 2012 Mar; 42(3):202-7. PubMed ID: 22246718
[TBL] [Abstract][Full Text] [Related]
5. [Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer].
Heidenreich A; Marx FJ; Peters HJ
Urologe A; 1999 Nov; 38(6):586-91. PubMed ID: 10591805
[TBL] [Abstract][Full Text] [Related]
6. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
Dash A; Galsky MD; Vickers AJ; Serio AM; Koppie TM; Dalbagni G; Bochner BH
Cancer; 2006 Aug; 107(3):506-13. PubMed ID: 16773629
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
8. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy preceding cystectomy for bladder cancer.
Sonpavde G; Amiel GE; Mims MP; Hayes TG; Lerner SP
Expert Opin Pharmacother; 2008 Aug; 9(11):1885-93. PubMed ID: 18627327
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.
Dreicer R; Gustin DM; See WA; Williams RD
J Urol; 1996 Nov; 156(5):1606-8. PubMed ID: 8863548
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
12. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Wood DP
J Urol; 2013 Dec; 190(6):2019. PubMed ID: 24209516
[No Abstract] [Full Text] [Related]
13. Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder.
McLaren DB
Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):503-7. PubMed ID: 16238137
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder.
Ennis RD
Curr Oncol Rep; 2004 May; 6(3):230-6. PubMed ID: 15066235
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
16. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
Matveev BP; Figurin KM
Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
[TBL] [Abstract][Full Text] [Related]
17. Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?
Tachibana I; Bandali E; Calaway AC; Krishnan N; Cheng L; Adra N; Kaimakliotis HZ
Urol Oncol; 2020 Nov; 38(11):850.e1-850.e7. PubMed ID: 32693973
[TBL] [Abstract][Full Text] [Related]
18. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
[TBL] [Abstract][Full Text] [Related]
19. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
